Patents Issued in May 2, 2017
-
Patent number: 9637488Abstract: The present application discloses a novel class of heterocycles as class I PI3Ks inhibitors. The compounds claimed herein could be used alone or in combination therapies for the treatment of a wide range of disorders such as autoimmune, inflammatory and allergic diseases, asthma, COPD, parasitic infections, diabetes, and cancer.Type: GrantFiled: January 27, 2016Date of Patent: May 2, 2017Inventor: Fuqiang Ruan
-
Patent number: 9637489Abstract: The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.Type: GrantFiled: September 4, 2015Date of Patent: May 2, 2017Assignee: JANUS BIOTHERAPEUTICS, INC.Inventors: Grayson B. Lipford, Charles M. Zepp
-
Patent number: 9637490Abstract: The present invention concerns novel compounds of Formula (I): wherein R1, R2, R3, R4, R5 and R6 have the meaning defined in the claims. The compounds according to the present invention are active mainly against dermatophytes and systemic fungal infections. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.Type: GrantFiled: June 1, 2011Date of Patent: May 2, 2017Assignee: Janssen Pharmaceutica NVInventors: Lieven Meerpoel, Louis Jules Roger Marie Maes, Kelly de Wit
-
Patent number: 9637491Abstract: The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.Type: GrantFiled: October 18, 2013Date of Patent: May 2, 2017Assignee: ORIGENIS GMBHInventors: Michael Almstetter, Michael Thormann, Andreas Treml, Nadine Traube
-
Patent number: 9637492Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.Type: GrantFiled: February 11, 2015Date of Patent: May 2, 2017Assignee: Intellikine LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan
-
Patent number: 9637493Abstract: The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.Type: GrantFiled: December 18, 2013Date of Patent: May 2, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher Dinsmore, Francesc Xavier Fradera Llinas, Amit Ashokro Kudale, Michelle Machacek, Michael Hale Reutershan, Christopher Francis Thompson, B. Wesley Trotter, Liping Yang, Michael D. Altman, Stephane L. Bogen, Ronald J. Doll, Matthew E. Voss
-
Patent number: 9637494Abstract: The present invention relates to the compound of formula (I) and to compositions comprising the same and to the use of the compound and to compositions of the compound in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compound.Type: GrantFiled: April 7, 2016Date of Patent: May 2, 2017Assignee: Respivert, Ltd.Inventors: John King-Underwood, Kazuhiro Ito, Peter John Murray, George Hardy, Frederick Arthur Brookfield, Christopher John Brown
-
Patent number: 9637495Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 5, 2016Date of Patent: May 2, 2017Assignee: Eli Lilly and CompanyInventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
-
Patent number: 9637496Abstract: The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; R1 is H, alkyl, alkoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazoyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; R2 is H, alkyl, alkoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1, Methods of making the compounds of Formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I.Type: GrantFiled: March 12, 2014Date of Patent: May 2, 2017Assignee: Janssen Pharmaceutica NVInventors: Heather R. Coate, Curt A. Dvorak, Anne E. Fitzgerald, Terry P. Lebold, Cathy Preville, Brock T. Shireman
-
Patent number: 9637497Abstract: Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.Type: GrantFiled: September 6, 2016Date of Patent: May 2, 2017Assignee: Nerviano Medical Sciences, S.R.L.Inventors: Gabriella Traquandi, Maria Gabriella Brasca, Roberto D'Alessio, Paolo Polucci, Fulvia Roletto, Anna Vulpetti, Paolo Pevarello, Achille Panzeri, Francesca Quartieri, Ron Ferguson, Paola Vianello, Daniele Fancelli
-
Patent number: 9637498Abstract: In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: August 22, 2014Date of Patent: May 2, 2017Assignee: VANDERBILT UNIVERSITYInventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Michael S. Poslusney, James C. Tarr, Bruce J. Melancon
-
Patent number: 9637499Abstract: Compounds of the general formula I wherein each of m and n is independently 0 or 1; R1 and R2, together with the carbon atom to which they are attached, form a heterocyclic ring comprising one or two heteroatoms selected from oxygen, sulfur, —S(O)— and —S(O)2—; R3 is —CHF2, —CF3, —OCHF2, —OCF3, —SCHF2 or —SCF3; X is a bond, —CH2—, or —NH—; A is aryl, cycloalkyl, cycloalkenyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkenyl, optionally substituted with one or more, same or different substituents selected from R4; and R4 is hydrogen, amino, thioxo, alkyl, haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, halogen, oxo, thia, or hydroxy; or pharmaceutically acceptable salts, hydrates or solvates thereof, have been found to exhibit PDE4 inhibiting activity, and may therefore be useful in the treatment of inflammatory diseases and disorders.Type: GrantFiled: October 1, 2015Date of Patent: May 2, 2017Assignee: LEO PHARMA A/SInventor: Simon Feldbaek Nielsen
-
Patent number: 9637500Abstract: This invention relates to crystalline solvates of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benz- oxadiazacyclotetradecine-3-carbonitrile, useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to pharmaceutical compositions comprising such crystalline solvates, and to methods of using such solvates and compositions in the treatment of abnormal cell growth in mammals, especially humans.Type: GrantFiled: June 17, 2014Date of Patent: May 2, 2017Assignee: Pfizer Inc.Inventors: Andrew James Jensen, Suman Luthra, Paul Francis Richardson
-
Patent number: 9637501Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.Type: GrantFiled: February 19, 2015Date of Patent: May 2, 2017Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITEDInventor: B. Narasimhulu Naidu
-
Patent number: 9637502Abstract: A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 30˜45° C. to form a solution, whose concentration is controlled within 0.05˜0.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 3˜5 times (in volume) of that of the solvent; followed by cooling the solution down to 0˜10° C. at a rate of 0.2˜1° C./min; continuing to stir for 1˜3 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.Type: GrantFiled: November 20, 2015Date of Patent: May 2, 2017Assignees: TIANJIN UNIVERSITY, HAINAN LINGKANG PHARMACEUTICAL CO., LTDInventors: Hongxun Hao, Linggang Tao, Zhihong Sun, Baohong Hou, Jun Lv, Qiuxiang Yin, Yongli Wang, Junbo Gong, Chuang Xie, Ying Bao
-
Patent number: 9637503Abstract: The method relates to the field of asymmetric allylic amination and comprises preparing a chiral N-substituted allylic amine compound from the corresponding allylic substrates and substituted hydroxylamines, in the presence of a catalyst, said catalyst comprising copper compounds and a chiral ligand. Examples of chiral amine compounds which can be made using the method include Vigabatrin, Ezetimibe Terbinafine, Naftifine 3-methylmorphine, Sertraline, Cinacalcet, Mefloquine hydrochloride, and Rivastigmine. There are over 20,000 known bioactive molecules with chiral N-substituted allylic amine substructure. The method may also be used to produce non-natural chiral ?-aminoacid esters, a sub-class of chiral N-substituted allylic amine compounds. Examples of ?-aminoacid ester which can be produced by the disclosed method, include, but are not limited to, N-(2-methylpent-1-en-3-yl)benzenamine and Ethyl 2-methylene-3-(phenylamino)butanoate.Type: GrantFiled: June 20, 2016Date of Patent: May 2, 2017Assignee: University of Louisiana at LafayetteInventors: Radhey S. Srivastava, Siva Murru
-
Patent number: 9637504Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.Type: GrantFiled: May 23, 2016Date of Patent: May 2, 2017Assignee: VENATORX PHARMACEUTICALS, INC.Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
-
Patent number: 9637505Abstract: 4-Amino-6-(heterocyclic)picolinic acids and their derivatives; 6-amino-2-(heterocyclic)pyrimidine-4-carboxylates and their derivatives; and methods of using the same as herbicides.Type: GrantFiled: March 15, 2013Date of Patent: May 2, 2017Assignee: Dow AgroSciences LLCInventors: Joseph D. Eckelbarger, Jeffrey B. Epp, Stephen Craig Fields, Lindsey G. Fischer, Natalie C. Giampietro, Katherine A. Guenthenspberger, Christian T. Lowe, Jeff Petkus, Joshua Roth, Norbert M. Satchivi, Paul R. Schmitzer, Thomas L. Siddall, Nick X. Wang
-
Patent number: 9637506Abstract: The invention relates to a method for producing compounds containing isocyanate and silane groups by reacting at least A) one monomeric diisocyanate containing aliphatically, cycloaliphatically, araliphatically and/or aromatically bonded isocyanate groups with B) a mercaptosilane, characterized in that component A) is reacted with component B) in an equivalent ratio of isocyanate groups to mercapto groups of at least 06:01 to at most 40:1. Furthermore, the invention relates to the products which can be obtained using the method according to the invention, and to a composition containing compounds that contain isocyanate and silane groups. Moreover, the invention relates to the use of the products which can be obtained using the method according to the invention and the composition according to the invention as starting components in the production of silane group-containing polyurethanes, cross-linkable binders, varnish, and raw materials for sealants or adhesives.Type: GrantFiled: August 29, 2013Date of Patent: May 2, 2017Assignee: Covestro Deutschland AGInventor: Hans-Josef Laas
-
Patent number: 9637507Abstract: A synthetic process of producing liquid tin(II) alkoxides for use as either catalysts in the synthesis of lactide or as initiators in the polymerization of cyclic ester monomers to yield biodegradable polyesters is described. The synthetic process employs anhydrous tin(II) chloride dissolved in n-heptane mixed with dry diethylamine. Alcohols, ROH, in which the R groups are n-C4H9, n-C6H13, and n-C8H17 are added to the reaction mixture and stirred for 12 hours. The reaction mixture is then filtered under nitrogen or argon before being evaporated to dryness to yield the three tin(II) alkoxides, namely: tin(II) n-butoxide, tin(II) n-hexoxide, and tin(II) n-octoxide. All three tin(II) alkoxides are viscous, dark yellow liquids which are highly soluble in most common organic solvents. Furthermore, they can all be stored under an inert atmosphere for long periods without any significant change in their reactivity and, therefore, in their effectiveness as catalysts/initiators.Type: GrantFiled: October 30, 2013Date of Patent: May 2, 2017Assignee: CHIANG MAI UNIVERSITYInventors: Puttinan Meepowpan, Winita Punyodom, Robert Molloy
-
Patent number: 9637508Abstract: Provided are ligand compounds containing two or more diphosphinoamine functional groups, where the two or more diphosphinoamine functional groups are linked by 4 carbon atoms, a catalyst system including the ligand compounds for olefin oligomerization, and a method for olefin oligomerization using the same. The catalyst system for olefin oligomerization according to the present invention has excellent catalytic activity, and yet, exhibits high selectivity to 1-hexene and 1-octene, thus enabling efficient preparation of alpha-olefin.Type: GrantFiled: November 18, 2014Date of Patent: May 2, 2017Assignee: LG CHEM, LTD.Inventors: Yong Ho Lee, Eun Ji Shin, Seok Pil Sa, Ki Soo Lee
-
Patent number: 9637509Abstract: Provided are ligand compounds selected from among N-(diphenylphosphino)-1,1-diphenyl-N-(4-phenylbutan-2-yl)phosphinamine and N4,N4-bis(diphenylphosphino)-N1,N1-diethylpentane-1,4-diamine, a catalyst system for olefin oligomerization, and a method for olefin oligomerization using the same. The catalyst system for olefin oligomerization has excellent catalytic activity, and yet, exhibits high selectivity to 1-hexene or 1-octene, thus enabling more efficient preparation of alpha-olefin.Type: GrantFiled: November 10, 2014Date of Patent: May 2, 2017Assignee: LG CHEM, LTD.Inventors: Eun Ji Shin, Yong Ho Lee, Seok Pil Sa, Ki Soo Lee
-
Patent number: 9637510Abstract: A method for preparing a ruthenium carbene complex precursor includes reacting a ruthenium refinery salt with a hydrogen halide to form a ruthenium intermediate, and reacting the ruthenium intermediate with an L-type ligand to form the ruthenium carbene complex precursor. A method for preparing a ruthenium vinylcarbene complex includes converting a ruthenium carbene complex precursor into a ruthenium hydrido halide complex, and reacting the ruthenium hydrido halide complex with a propargyl halide to form the ruthenium vinylcarbene complex. A method for preparing a ruthenium carbene complex includes converting a ruthenium carbene complex precursor into a ruthenium carbene complex having a structure (PR1R2R3)2Cl2Ru?CH—R4, wherein R1, R2, R3, and R4 are alike or different, and wherein covalent bonds may optionally exist between two or more of R1, R2, and R3 and/or two of R1, R2, and R3 taken together may optionally form a ring with phosphorous.Type: GrantFiled: January 30, 2015Date of Patent: May 2, 2017Assignee: Elevance Renewable Sciences, Inc.Inventors: Linda A. Kunz, Steven A. Cohen
-
Patent number: 9637511Abstract: A method of forming a thin film including vaporizing a nickel compound on a substrate using a heterostructured nickel compound including a nickel amidinate ligand and an aliphatic alkoxy group and providing a vapor containing the vaporized nickel compound onto the substrate, thereby forming a nickel-containing layer. Vaporizing the nickel compound on the substrate is performed in an atmosphere in which at least one selected from plasma, heat, light, and voltage is applied.Type: GrantFiled: February 16, 2015Date of Patent: May 2, 2017Assignees: SAMSUNG ELECTRONICS CO., LTD., ADEKA CORPORATIONInventors: Sang-chul Youn, Gyu-hee Park, Youn-joung Cho, Haruyoshi Sato, Takanori Koide, Naoki Yamada, Akio Saito, Akihiro Nishida
-
Patent number: 9637512Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.Type: GrantFiled: January 10, 2014Date of Patent: May 2, 2017Assignee: Gilead Pharmasset LLCInventors: Byoung-Kwon Chun, Ganapati Reddy Pamulapati, Suguna Rachakonda, Bruce Ross, Michael Joseph Sofia, Peiyuan Wang, Hai-Ren Zhang
-
Patent number: 9637513Abstract: The present invention provides compositions useful for biomolecule storage comprising a water soluble inorganic compound, a stabilizer, or a combination thereof. The present invention also provides methods of using the compositions of the invention to store biomolecules in the dry state and in solution, as well as sample carriers and kits comprising compositions of the invention.Type: GrantFiled: January 14, 2015Date of Patent: May 2, 2017Assignee: GenTegra LLCInventors: Michael Hogan, Michael Saghbini, David Wong
-
Patent number: 9637514Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit Hedgehog signaling. Also described herein are methods for using such Hedgehog signaling inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of Hedgehog signaling.Type: GrantFiled: February 26, 2016Date of Patent: May 2, 2017Assignee: MAX BIOPHARMA, INC.Inventors: Frank Stappenbeck, Yi Chiao Fan
-
Patent number: 9637515Abstract: The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.Type: GrantFiled: November 6, 2007Date of Patent: May 2, 2017Assignee: JINA PHARMACEUTICALS, INC.Inventors: Moghis U. Ahmad, Shoukath M. Ali, Ateeq Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Patent number: 9637516Abstract: The invention relates to novel betulinic acid derivatives and related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.Type: GrantFiled: December 26, 2013Date of Patent: May 2, 2017Assignee: HETERO RESEARCH FOUNDATIONInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Lanka Vl Subrahmanyam, Gazula Levi David Krupadanam, Mukkera Venkati, Neela Sudhakar, Kallem Srinivas Reddy
-
Patent number: 9637517Abstract: Disclosed in the present invention is a method for preparing Exenatide. Serine resin is obtained through a first coupling of serine and resin and successively with amino acids through a second coupling to obtain a peptide resin with a sequence as shown by SEQ ID No. 1; Exenatide resin is obtained through a third coupling of histidine containing a protecting group or salts thereof and the peptide resin with a sequence as shown by SEQ ID No. 1, then it is cracked and purified to obtain purified Exenatide peptide. The method for preparing Exenatide of the present invention inhibits the formation of D-His-Exenatide, and thereby improves the yield and purity of Exenatide.Type: GrantFiled: October 31, 2012Date of Patent: May 2, 2017Assignee: HYBIO PHARMACEUTICAL CO., LTD.Inventors: Pengcheng Mi, Jian Liu, Yaping Ma, Jiancheng Yuan
-
Patent number: 9637518Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.Type: GrantFiled: July 10, 2014Date of Patent: May 2, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Kyoung S. Kim, Liping Zhang, Erik M. Stang
-
Patent number: 9637519Abstract: A peptide according to the present invention can perform a function identical or similar to the function of natural CTLA-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (CD80 and CD86) to inhibit activity of T cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, IL-2 and IFN-?). As a result, a composition comprising the peptide according to the present invention exhibits excellent effects in terms of preventing, treating, or improving Th1-mediated immune diseases. Therefore, the superior activity and stability of the peptide according to the present invention can be useful when applied to medicine, quasi-drugs, and cosmetics.Type: GrantFiled: October 25, 2013Date of Patent: May 2, 2017Assignee: CAREGEN CO., LTD.Inventors: Young Ji Chung, Eun Mi Kim, Eung-Ji Lee, Tae-Hoon Lee, Young-Min Lee
-
Patent number: 9637520Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I) wherein the single elements T or P are ?-amino acid residues connected from the carbonyl (C?O) point of attachment to the nitrogen (N) of the next element in clockwise direction and wherein said elements, depending on their positions in the chain, are defined in the description and the claims have the property to act on the receptor CXCR7. Thus, these ?-hairpin peptidomimetics can be useful in the treatment or prevention of diseases or conditions in the area of dermatological disorders, metabolic diseases, inflammatory diseases, fibrotic diseases, infectious diseases, neurological diseases, cardiovascular diseases, respiratory diseases, gastro-intestinal tract disorders, urological diseases, ophthalmic diseases, stomatological diseases, haematological diseases and cancer; or the mobilization of stem cells.Type: GrantFiled: July 9, 2015Date of Patent: May 2, 2017Assignee: POLYPHOR AGInventors: Frank Otto Gombert, Alexander Lederer, Ralf Löwe, Daniel Obrecht, Barbara Romagnoli, Johann Zimmermann, Kalpana Patel
-
Patent number: 9637521Abstract: Dengue Fever (DF) and Dengue Hemorrhagic Fever (DHR) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive T cell responses. Currently, there are no available tools to assess protective T cell responses during infection or post vaccination. The present invention incorporates immunoproteomics to uncover novel HLA-A2 specific epitopes derived from Dengue Virus (DV)-infected cells. These epitopes are conserved with epitope-specific CTLs cross-reacting against all four DV serotypes. These epitopes have potential as new informational and diagnostic tools to characterize T cell immunity in Dengue virus (DV) infection, and serves as a universal vaccine candidate complementary to current vaccines.Type: GrantFiled: June 28, 2012Date of Patent: May 2, 2017Assignee: Emergex Vaccines Holdings LimitedInventor: Ramila Philip
-
Patent number: 9637522Abstract: Vaccine compositions and methods of producing and using the same are provided, which compositions comprise a modified HA stem domain in a trimeric configuration.Type: GrantFiled: May 23, 2013Date of Patent: May 2, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Yuan Lu, James R. Swartz
-
Patent number: 9637523Abstract: The invention provides a combination of an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 1 or a homolog thereof, and an isolated peptide or peptidomimetic that includes the sequence of SEQ ID NO: 2. The invention also provides a method of treating a BCR-ABL associated disease or a c-ABL associated disease in a subject. The method is based on the use of the aforementioned combination of one or more isolated peptides or peptidomimetics.Type: GrantFiled: August 30, 2013Date of Patent: May 2, 2017Assignee: Westfaelische Wilhelms-Universitaet MuensterInventors: Eike-Roman Hrincius, Stephan Ludwig, Christina Ehrhardt
-
Patent number: 9637524Abstract: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.Type: GrantFiled: November 5, 2014Date of Patent: May 2, 2017Assignee: The Regents of the University of CaliforniaInventors: R. Holland Cheng, Li Xing
-
Patent number: 9637525Abstract: The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy.Type: GrantFiled: May 1, 2015Date of Patent: May 2, 2017Assignee: THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETHInventors: Timothy Foster, Judy Higgins, Elisabet Josefsson, Joan Geoghegan, Andrej Tarkowski
-
Patent number: 9637526Abstract: Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.Type: GrantFiled: December 1, 2015Date of Patent: May 2, 2017Assignee: Morphotek, Inc.Inventors: Abdellah Sentissi, Douglas B. Jacoby
-
Patent number: 9637527Abstract: A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.Type: GrantFiled: March 13, 2013Date of Patent: May 2, 2017Assignee: JAMES COOK UNIVERSITYInventors: Alex Loukas, Severine Navarro
-
Patent number: 9637528Abstract: The invention provides directed evolution methods for improving the folding, solubility and stability (including thermostability) characteristics of polypeptides. In one aspect, the invention provides a method for generating folding and stability-enhanced variants of proteins, including but not limited to fluorescent proteins, chromophoric proteins and enzymes. In another aspect, the invention provides methods for generating thermostable variants of a target protein or polypeptide via an internal destabilization baiting strategy. Internally destabilization a protein of interest is achieved by inserting a heterologous, folding-destabilizing sequence (folding interference domain) within DNA encoding the protein of interest, evolving the protein sequences adjacent to the heterologous insertion to overcome the destabilization (using any number of mutagenesis methods), thereby creating a library of variants. The variants in the library are expressed, and those with enhanced folding characteristics selected.Type: GrantFiled: October 2, 2008Date of Patent: May 2, 2017Assignee: Los Alamos National Security, LLCInventors: Andrew M. Bradbury, Csaba Kiss, Geoffrey S. Waldo
-
Patent number: 9637529Abstract: The present invention provides SERF2, a nucleic acid encoding said SERF2 or a cell expressing SERF2 for use as a medicament, in particular for use for use in treating or preventing an atrophy disease or condition or for increasing cellular growth in a patient such as sarcopenia, cachexia, dystrophy, hypoplasia, hypotonia, or muscle loss, as well as in vitro methods suitable for cell culture proliferation and pharmaceutical compositions.Type: GrantFiled: December 13, 2013Date of Patent: May 2, 2017Assignee: SIMU TRADE CONSULTING GMBH & CO. LEASING KGInventor: Rudolf Berger
-
Patent number: 9637530Abstract: Disclosed are cysteine variants of interleukin-11 (IL-11) and methods of making and using such proteins in therapeutic applications.Type: GrantFiled: April 25, 2014Date of Patent: May 2, 2017Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox, III
-
Patent number: 9637531Abstract: The present invention relates to compositions, methods and kits for delivery of an IGF-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express proteoglycans. More specifically, the present invention relates to fusion proteins comprising a heparin binding protein (HB) comprising SEQ ID NO: 1 or SEQ ID NO: 2. Other aspects relate to use of a HB-IGF-1 fusion proteins in methods to deliver IGF-1 to the cartilage for the treatment of a cartilage related disease and disorder in a subject.Type: GrantFiled: June 25, 2013Date of Patent: May 2, 2017Assignee: The Brigham and Women's Hospital, IncInventors: Richard T. Lee, Parth Patwari, Francesco Loffredo, James Pancoast, Zheng Xin Dong, Todd Vannelli
-
Patent number: 9637532Abstract: The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from PD-1 or a ligand of PD-1, and a composition or kit comprising thereof, its use in immune response etc.Type: GrantFiled: July 10, 2014Date of Patent: May 2, 2017Assignee: VLP Therapeutics, LLCInventors: Wataru Akahata, Ryuji Ueno
-
Patent number: 9637533Abstract: The present invention relates to a method for increasing embryo implantation rate in mother's uterus in mammals by administering to the uterus of a mammal an effective amount of beta-galactoside-binding lectin or derivatives thereof, as well as to a product comprising said lectin.Type: GrantFiled: December 9, 2011Date of Patent: May 2, 2017Assignees: UNIVERSIDADE DE SÃO PAULO-USP, INPRENHA BIOTECHNOLOGIA E DESENVOLVIMENTO AVANçADO LTDA-MEInventors: Marcelo Dias Baruffi, Erika da Silva Carvalho Morani, Marcelo Roncoletta, Camillo del Cistia Andrade, Lilian Cataldi Rodrigues
-
Patent number: 9637534Abstract: The present provides fusion proteins comprising PDGF and VEGF binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided.Type: GrantFiled: March 13, 2014Date of Patent: May 2, 2017Assignee: GENZYME CORPORATIONInventors: Peter Pechan, Jeffery Ardinger, Hillard Rubin, Samuel Wadsworth, Abraham Scaria
-
Patent number: 9637535Abstract: The present invention provides interleukin-33 (IL-33) antagonists comprising one or more IL-33-binding domains and one or more multimerizing domains and methods of using the same. According to certain embodiments of the invention, the IL-33-binding domains can comprise an IL-33-binding portion of an ST2 protein and/or an extracellular portion of an IL-1RAcP protein. The IL-33 antagonists of the invention are useful for the treatment of diseases and disorders associated with IL-33 signaling and/or IL-33 cellular expression, such as infectious diseases, inflammatory diseases, allergic diseases and fibrotic diseases.Type: GrantFiled: March 14, 2014Date of Patent: May 2, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Andrew J. Murphy, Nicholas J. Papadopoulos, Jamie Orengo
-
Patent number: 9637536Abstract: Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are provided. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are provided, along with methods for isolating such genes and for isolating and expressing such receptors.Type: GrantFiled: April 27, 2015Date of Patent: May 2, 2017Assignee: Senomyx, Inc.Inventors: Jon Elliot Adler, Sergey Zozulya, Xiaodong Li, Shawn O'Connell, Lena Luukkonen
-
Patent number: 9637537Abstract: The present invention relates to the murine monoclonal antibody (mAb) 11B9 and to mAb 62 each of which target major neutralizing epitopes of influenza A H7 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H7 influenza using murine mAb 11B9, mAb 62 or fragments thereof. The present invention further relates to methods and kits for determining, identifying and/or quantifying (a) influenza A hemagglutinin in a sample or vaccine or (b) an antibody against influenza A hemagglutinin.Type: GrantFiled: August 23, 2013Date of Patent: May 2, 2017Assignee: TEMASEK LIFE SCIENCES LABORATORIES LIMITEDInventors: Hwei-Sing Jimmy Kwang, Fang He, Rajesh Kumar Subaschandrabose